News

Pfizer uses HiFiBiO’s brand-new technology to discover unique antibodi


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Pfizer uses HiFiBiO’s brand-new technology to discover unique antibodies

 

Date: 18/08/2015

French biotech startup HiFiBiO announced today it has achieved a milestone in its research collaboration with American giant Pfizer to develop new antibody therapeutics. The new milestone is triggering an undisclosed payment to HiFiBiO.
The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform for deep mining of immune repertoires. The platform uses single cell-based screening of entire antibody-secreting B cell populations along with bar coded next generation sequencing and rapid DNA synthesis to identify multiple leads and enable the development of potential optimized antibody candidates.


For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019